{"id":14694,"date":"2025-03-27T11:47:19","date_gmt":"2025-03-27T15:47:19","guid":{"rendered":"https:\/\/www.biotech.ca\/?p=14694"},"modified":"2025-03-27T11:47:20","modified_gmt":"2025-03-27T15:47:20","slug":"efforts-communs-de-toutes-les-provinces-et-les-territoires-afin-dameliorer-lacces-a-de-nouvelles-solutions-de-traitement-pour-les-canadiens-atteints-de-maladies-rares","status":"publish","type":"post","link":"https:\/\/www.biotech.ca\/fr\/news\/efforts-communs-de-toutes-les-provinces-et-les-territoires-afin-dameliorer-lacces-a-de-nouvelles-solutions-de-traitement-pour-les-canadiens-atteints-de-maladies-rares\/","title":{"rendered":"Efforts communs de toutes les provinces et les territoires afin d\u2019am\u00e9liorer l\u2019acc\u00e8s \u00e0 de nouvelles solutions de traitement pour les Canadiens atteints de maladies rares"},"content":{"rendered":"\n<p>BIOTECanada salue l\u2019accord bilat\u00e9ral conclu entre le gouvernement du Canada et la province de Qu\u00e9bec, qui s\u2019inscrit dans un engagement pancanadien envers la Strat\u00e9gie nationale visant les m\u00e9dicaments pour le traitement des maladies rares. Ce jalon est le fruit des efforts communs de toutes les provinces et les territoires afin d\u2019am\u00e9liorer l\u2019acc\u00e8s \u00e0 de nouvelles solutions de traitement pour les Canadiens atteints de maladies rares.<\/p>\n\n\n\n<p>Des entreprises en d\u00e9marrage aux grandes multinationales, les membres de BIOTECanada font des perc\u00e9es scientifiques et assurent l\u2019acc\u00e8s \u00e0 des m\u00e9dicaments qui transforment la vie des patients. Nous continuerons de travailler activement avec nos partenaires f\u00e9d\u00e9raux pour nous assurer que les Canadiens atteints de maladies rares sont toujours au c\u0153ur de la prise de d\u00e9cisions \u00e9clair\u00e9es concernant les nouvelles th\u00e9rapies vitales.<\/p>\n\n\n\n<p>Pour consulter tous les accords bilat\u00e9raux, visitez&nbsp;:&nbsp;<a href=\"https:\/\/www.canada.ca\/fr\/sante-canada\/organisation\/transparence\/ententes-en-matiere-de-sante\/priorites-partagees-matiere-sante\/accords-bilateraux-pour-medicaments-pour-traitement-maladies-rares.html\" target=\"_blank\" rel=\"noreferrer noopener\">www.canada.ca\/fr\/sante-canada\/organisation\/transparence\/ententes-en-matiere-de-sante\/priorites-partagees-matiere-sante\/accords-bilateraux-pour-medicaments-pour-traitement-maladies-rares.html<\/a>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BIOTECanada salue l\u2019accord bilat\u00e9ral conclu entre le gouvernement du Canada et la province de Qu\u00e9bec, qui s\u2019inscrit dans un engagement pancanadien envers la Strat\u00e9gie nationale visant les m\u00e9dicaments pour le<\/p>\n<p class=\"more-link-box\"><a class=\"more-link button_a arrow\" href=\"https:\/\/www.biotech.ca\/fr\/news\/efforts-communs-de-toutes-les-provinces-et-les-territoires-afin-dameliorer-lacces-a-de-nouvelles-solutions-de-traitement-pour-les-canadiens-atteints-de-maladies-rares\/\">Lire la suite<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"rank_math_lock_modified_date":false,"inline_featured_image":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[58],"tags":[45],"class_list":["post-14694","post","type-post","status-publish","format-standard","category-declarations","tag-home-fr","entry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/posts\/14694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/comments?post=14694"}],"version-history":[{"count":1,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/posts\/14694\/revisions"}],"predecessor-version":[{"id":14695,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/posts\/14694\/revisions\/14695"}],"wp:attachment":[{"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/media?parent=14694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/categories?post=14694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/tags?post=14694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}